Siderosis is a systemic disease characterized by excessive accumulation of iron in the body, leading to organ and tissue damage. It can result from both inherited disorders, such as hemochromatosis, and acquired factors, including repeated blood transfusions or excessive iron intake. During the process of pathological accumulation of iron, accumulation occurs in various organs, including the liver, heart, and pancreas, which can lead to serious consequences, such as liver cirrhosis, cardiomyopathy, and diabetes. Knowledge of the causes, mechanisms, and consequences of siderosis is key to early diagnosis and successful treatment of this condition.
History of the disease and interesting historical facts
Siderosis was first described in medical literature in the early 20th century, but cases of iron accumulation in the body had been known for a long time before that. One of the first to pay attention to this disease was the French physician Jean Sulpi, who in 1865 described clinical manifestations associated with changes in the liver caused by increased iron levels. In 1935, after studying cases of liver damage in patients, it became apparent that siderosis was the result of glandular overload. Historically, siderosis was also associated with various professions related to iron work, including steelworkers and blacksmiths. This prompted the need to study the impact of occupational factors on the health of workers, which eventually led to the development of appropriate work standards.
Epidemiology
The prevalence of siderosis varies depending on the population and the etiology of the disease. According to epidemiological studies, hereditary hemochromatosis occurs in approximately 1 in 200-300 people in the European population. At the same time, acquired forms of siderosis, resulting from repeated transfusions or excessive iron intake, are more often detected in certain groups of patients, for example, in people with chronic anemia requiring regular replacement therapy. It is important to note that in some Asian and African countries, the level of siderosis may be higher due to specific genetic predispositions and the environment. Statistics show that with the increase in the number of transfusions in patients with chronic diseases, the incidence of acquired siderosis also increases.
Genetic predisposition to this disease
There are known genes associated with hereditary hemochromatosis, the main type of siderosis. In particular, mutations in the HFE gene, located on chromosome 6, play a key role in the pathogenesis of the disease. The most common mutation, C282Y, leads to a decrease in the body's ability to regulate iron absorption, which directly leads to its excess accumulation. Other genes, such as HAMP and TFR2, may also be involved in the development of siderosis, although less frequently. Hereditary hemochromatosis has a characteristic autosomal recessive transmission, which means that two mutant alleles are necessary for the disease to manifest. In addition, genetically determined differences in iron metabolism between different populations can be identified, which affects the frequency of disease manifestations.
Risk factors for the development of this disease
There are several risk factors that contribute to the development of siderosis. Among them are:
- Genetic mutations such as C282Y in the HFE gene;
- Old age, since the accumulation of iron in the body increases with age;
- Ethnicity resulting in high levels of genetic hemochromatosis in certain populations;
- Chronic diseases requiring regular transfusions (eg, thalassemia);
- Excessive consumption of iron supplements or iron-rich foods;
- Chronic liver diseases that may impair iron metabolism;
- Diseases that affect its absorption, such as celiac disease.
These factors collectively contribute to an increased likelihood of developing clinically significant siderosis, which requires careful monitoring and management in susceptible patients.
Diagnosis of this disease
Diagnosis of siderosis involves a comprehensive clinical examination, laboratory and imaging studies. Key symptoms may include fatigue, joint pain, liver dysfunction and cardiovascular disorders. Laboratory tests such as ferritin and serum iron levels are key to identifying excess iron accumulation. In some cases, a liver biopsy may be necessary to assess the extent of iron overload. Radiological studies including MRI can help visualize iron accumulation in organs.
Differential diagnosis includes exclusion of other conditions such as Viking disease and hereditary anemias that may cause similar clinical manifestations. It is important to consider the presence of comorbidities, as they may influence the final diagnosis and treatment strategy.
Treatment
Treatment of siderosis depends on its etiology and severity. The main treatment method is venesection, which removes excess iron from the body. This procedure may be recommended not only in cases of hereditary hemochromatosis, but also in acquired forms of siderosis. Pharmacological treatment may include iron chelating agents such as dextramethyldexferoxamine, which help remove excess iron.
In some cases, surgery, such as a liver transplant, may be necessary if there is severe organ damage. Other approaches include following a diet that restricts iron-rich foods, which can also reduce iron levels in the body.
List of medications used to treat this disease
The main medications used to treat siderosis include:
- Dexferoxamine is an iron chelation drug;
- Deferiprone is an oral iron chelator;
- Deferasirox is a drug used to remove excess iron;
- Vitamin C (in limited quantities) – may enhance iron absorption and excretion.
These drugs help control iron levels in the body and prevent the development of serious complications.
Disease monitoring
Monitoring of patients with siderosis includes regular check-ups of iron levels, ferritin, and other biochemical markers. Prognosis depends on the extent of organ damage at diagnosis and the effectiveness of treatment. Patients who receive adequate therapy experience improvement and a reduced risk of complications such as liver cirrhosis or cardiomyopathy. It is also important to consider possible complications that may arise, including diabetes and cardiovascular disease, which requires a comprehensive approach to patient management.
Age-related features of the disease
Siderosis can manifest itself in different age groups, but clinical manifestations may vary. In children and adolescents, the disease may be asymptomatic or manifest itself as mild deficiencies. In adulthood, more pronounced symptoms are usually observed, including liver and heart dysfunction. In the elderly, the risk of developing severe forms of siderosis increases significantly due to existing chronic diseases and changes in metabolism. Thus, the patient's age is an important factor influencing the choice of treatment tactics and monitoring of the disease.
Questions and Answers
- What is siderosis? Siderosis is a disease characterized by excess accumulation of iron in the body, which can lead to damage to important organs and tissues.
- What are the main causes of siderosis? The main causes are inherited disorders such as hemochromatosis, as well as acquired factors including repeated blood transfusions and excessive iron intake.
- What symptoms do patients with siderosis notice? Symptoms may include fatigue, joint pain, jaundice, cardiovascular problems, and pancreatic problems.
- How is siderosis diagnosed? Diagnosis includes laboratory tests of iron and ferritin levels, liver biopsy and radiological studies.
- How is siderosis treated? Treatment includes venesection, iron chelation, and, in some cases, surgery to correct the effects of iron overload.
A clinical understanding of siderosis and the factors that contribute to its development allows physicians to develop effective strategies to prevent and treat the condition, ultimately improving the quality of life of patients.
